VULM 1457 significantly reduces atherogenic activity in animal experimental atherosclerosis[1].
VULM 1457 protect the hearts of diabetic–hypercholesterolaemic rats against ischaemia/reperfusion injury in vivo[2].
VULM 1457 (50 mg/kg/day; administered as an admixture to the fat-cholesterol diet for 5 days) significantly decreases plasma total cholesterol levels (1.7±0.1 mM vs. 2.9±0.5 mM in diabetic–hypercholesterolaemic animals). The hypolipidaemic effect of VULM 1457 is also observed in the liver of DM-HCH rats (3.9±0.2 mg/g vs. 7.4±1.0 mg/g)[2].
| Animal Model: | Male Wistar rats (250-300 g body weight), fed a standard diet and tap water ad libitum[2] |
| Dosage: | 50 mg/kg/day |
| Administration: | Administered as an admixture to the fat-cholesterol diet for 5 days |
| Result: | Improved the overall myocardial ischaemia-reperfusion injury outcomes in the diabetic-hypercholesterolaemic rats by suppressing arrhythmogenesis as well as by reducing myocardial necrosis, aside from remarkable hypolipidaemic activity. |
![N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea Structure](/CAS/GIF/228544-65-8.gif)
![N-[2,6-BIS(1-METHYLETHYL)PHENYL]-N'-[4-[(4-NITROPHENYL)THIO]PHENYL]UREA pictures](/ProductImageEN3/2026-07/Small/8487c2b8-d4ec-48cb-98aa-2ee0a91a3435.jpg)
